We approach two groups of strategies to achieve a strong return and outperform the market
Main part Of the portfolio consists of a diversified exposure to the biopharma sector
Well-established companies with a number of commercialized products and stable cash flows that are paying dividends to their shareholders
Companies with products at late stages of research or products at early stages of commercialization
Companies with promising products in clinical research, and/or a large preclinical share of pipeline
Limited speculative part; advanced risk analysis
Companies with expected business updates, Phase 1-3 results, pending FDA decision, or legal proceedings, which may significantly affect the price
Companies that we perceive to be undervalued due to the exaggerated market reaction to a certain business event (such as news about research results)
Companies that we perceive to be undervalued due to the exaggerated market reaction to a certain business event (such as news about research results)
We developed fundamental expertise in four groups of technologies to identify the best investment targets
CAR T-cells, RNAi and CRISPR technologies that modify the expression of an individual’s genes or repair abnormal genes
Restoring a certain cell population or using cells as carriers of therapeutic cargo
Aimed to prevent or mitigate infections, as well as treat people who have already been infected by a virus or bacteria
Stimulate the patient's immune system to attack pathogen cells
Reverse the damage that accumulates with age and leads to tissue dysfunction: accumulated genetic damage; Epigenetic alterations; Aging-associated changes in cell signaling; Loss of telomere-protective sequences
Focus on novel therapeutic approaches aimed at meeting unmet needs in either blockbuster (cancer, cardiovascular diseases) or orphan disease indications
Replacement of dysfunctional cells, tissues and organs (appearing as a result of stroke, hepatitis, chronic renal insufficiency, etc.) with healthy ones
We employ fundamental analysis and event-driven strategies to make long and short investments in publicly traded biopharmaceutical and medical device companies
Screening
Analysis
Deal executionOur team consists of professionals in healthcare and the financial industry
If you are an investor interested in learning more about our fund, please send us a message
